Assessment of variability in life expectancy in older men by use of new comorbidity indices. A nationwide population-based study
DOI:
https://doi.org/10.2340/sju.v59.42504Keywords:
Life expectancy, comorbidity, prostate cancerAbstract
N/A
Downloads
References
Meacock R, Sutton M, Kristensen SR, et al. Using survival analysis to improve estimates of life year gains in policy evaluations. Med Decis Making. 2017;37(4):415–426. https://doi.org/10.1177/0272989X16654444 DOI: https://doi.org/10.1177/0272989X16654444
Westerberg M, Irenaeus S, Garmo H, et al. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804. https://doi.org/10.1371/journal.pone.0296804 DOI: https://doi.org/10.1371/journal.pone.0296804
Gedeborg R, Sund M, Lambe M, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4): DOI: https://doi.org/10.1097/EDE.0000000000001358
607–615. https://doi.org/10.1097/EDE.0000000000001358 DOI: https://doi.org/10.1097/EDE.0000000000001358
Van Hemelrijck M, Ventimiglia E, Robinson D, et al. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Making. 2022;22(1):35. https://doi.org/10.1186/s12911-022-01766-0 DOI: https://doi.org/10.1186/s12911-022-01766-0
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–273. https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–284. https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396
Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the Charlson comorbidity index for register-based research in Sweden. Clin Epidemiol. 2021;13:21. https://doi.org/10.2147/CLEP.S282475 DOI: https://doi.org/10.2147/CLEP.S282475
Statistics Sweden. Population statistics 2024 [Internet]. Available from: https://www.scb.se/en/finding-statistics/statistics-by-subject-area/population/population-composition/population-statistics/ [cited date: 2024-10-11]
Westerberg M, Garmo H, Robinson D, et al. Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. J Clin Epidemiol. 2024;174:111504. https://doi.org/10.1016/j.jclinepi.2024.111504 DOI: https://doi.org/10.1016/j.jclinepi.2024.111504
Ventimiglia E, Gedeborg R, Styrke J, et al. Natural history of nonmetastatic prostate cancer managed with watchful waiting. JAMA Netw Open. 2024;7(6):e2414599. https://doi.org/10.1001/jamanetworkopen.2024.14599 DOI: https://doi.org/10.1001/jamanetworkopen.2024.14599
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marcus Westerberg, Mats Ahlberg, Andri Wilberg Orrason, Rolf Gedeborg
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
